TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Value of FEC-PET Combined With Endorectal MRI for Pre-therapeutic Staging of Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically diagnosed prostate cancer (needle biopsy)~* Radical prostatectomy as primary treatment~* No nutrition within 12 hours before Positron-Emission-Tomography (PET)~* No food containing choline within 24 hous before PET~* Age \> 50 years~Exclusion Criteria:~* Total endo-prothesis of the hip region~* Clinical or chemical detection of an acute infection~* Missing patient agreement~* Secondary cancer~* Surgical treatment within 3 month before PET~* Claustrophobia~* Medical drugs with choline~* Severe liver damage~* Cardiac infarction~* Bradycardia (pulse rate \< 55/min)~* Allergic reaction against Neurotropan~* Bronchial asthma~* Cardiac pacemaker~* Small metal implants (e.g., clips, cochlea-implants, etc.)

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients with prostate carcinoma confirmed by needle biopsy, age \>50 years, planned radical prostatectomy with lymph-node dissection, fasting for \>12 hours before FEC-PET and an interval between biopsy and PET \>3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic kidney disease with an estimated glomerular filtration rate (as calculated by the Japanese GFR estimation equation) of =\<89 mL/min/1.73 m2, and not required dialysis for 3 months since study completion~* The mean of two Hb values at screening test and Hb test (at least one week apart form the screening test) is \<10.0 g/dL, with a difference of ≤1.0 g/dL between the two values~* Both TSAT\>=5% and ferritin \>=30 ng/mL at screening test~* Serum folate ≥4.0 ng/mL and Vitamin B12 ≥180 pg/mL at screening test~Exclusion Criteria:~* Proliferative retinopathy, age-related macular degeneration, retinal vein occlusion and/or macular edema that is considered to require treatment~* Immunological disease with severe inflammation as assessed by the Investigator; even if the inflammation is in remission, the subject is excluded (e.g. lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, celiac disease, etc).~* Having a history of gastric/intestinal resection considered influential on the absorption of the drug in the gastrointestinal tract or evidence of active gastroparesis.~* Uncontrollable hypertension (more than one third blood pressure values of diastolic BP \>100 mmHg within 16 weeks prior to screening test including)~* Congestive heart failure (NYHA classification III or higher)~* Having a history of hospitalization for stroke, myocardial infarction or lung infarction within 24 weeks before screening test~* Positive for any of the following: anti-hepatitis C virus antibody (anti-HCV Ab); hepatitis B surface antigen (HBsAg); or human immunodeficiency virus (HIV)~* Anemia other than anemia due to low/absent renal production of EPO (e.g., iron deficiency anemia, hemolytic anemia, pancytopenia, etc)~* Using ESA, anabolic androgenic steroid, testosterone enanthate or mepitiostane within 6 weeks before screening test

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- ASP1517 low dose group (Type: EXPERIMENTAL): Oral
- ASP1517 middle dose group (Type: EXPERIMENTAL): Oral
- ASP1517 high dose group (Type: EXPERIMENTAL): Oral
- Placebo group (Type: PLACEBO_COMPARATOR): Oral

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Atopic Dermatitis for at least 3 months~* Investigator's Global Assessment (IGA) Score of 2 or 3~* Eczema Area Severity Index (EASI) score of 3-21~* Body Surface Area (BSA) of 2-20%~* Peak pruritus-Numerical Rating Scale (PPNRS) of Grade 2 or more~Exclusion Criteria:~* Other forms of dermatological diseases (other than atopic dermatitis)~* Fitzpatrick skin type score greater than 5~* Clinically significant abnormal ECG, vital signs, and laboratory values~* Infection with HBV, HCV, herpes zoster or tuberculosis

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PF-06700841 0.1% cream QD (Type: EXPERIMENTAL): PF-06700841 0.1% cream applied once daily (QD)
- PF-06700841 0.3% cream QD (Type: EXPERIMENTAL): PF-06700841 0.3% cream applied once daily (QD)
- PF-06700841 1% cream QD (Type: EXPERIMENTAL): PF-06700841 1% cream applied once daily (QD)
- PF-06700841 3% cream QD (Type: EXPERIMENTAL): PF-06700841 3% cream applied once daily (QD)
- PF-06700841 0.3% cream BID (Type: EXPERIMENTAL): PF-06700841 0.3% cream applied twice daily (BID)
- PF-06700841 1% cream BID (Type: EXPERIMENTAL): PF-06700841 1% cream applied twice daily (BID)
- Vehicle cream QD (Type: PLACEBO_COMPARATOR): Vehicle cream applied once daily (QD)
- Vehicle cream BID (Type: PLACEBO_COMPARATOR): Vehicle cream applied twice daily (BID)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long-term Study on the Side Effects of TRADIANCE in Japanese Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Japanese patients with Type 2 Diabetes mellitus (T2DM) who are prescribed with TRADIANCE® Combination Tablets AP or BP~* Patients who have never been treated with TRADIANCE® Combination Tablets AP or BP before enrolment~Exclusion Criteria:~None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subjects with type 2 Diabetes Mellitus (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Outpatients of either sex, 40 years or older, with a diagnosis of COPD (FEV1 65% predicted normal and FEV1/FVC 70%).~Exclusion Criteria:~Patients with significant diseases other than COPD that may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study, with a history of asthma or allergic rhinitis, who regularly use daytime oxygen therapy for more than 1 hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy or using oral corticosteroid me dication at unstable doses (i.e., less than 6 weeks on a stable dose) or at a dose in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day will be excluded.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- COMBIVENT Respimat 20/100 mcg (Type: EXPERIMENTAL): None
- COMBIVENT CFC-MDI 36/206 mcg (Type: EXPERIMENTAL): None
- Ipratropium Respimat 20 mcg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Ruxolitinib in Pancreatic Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Diagnosis of metastatic pancreatic cancer; subjects must have had measurable, or evaluable disease that was histologically confirmed~* Karnofsky performance status of ≥ 60~* Subjects must have failed 1st-line gemcitabine treatment for metastatic pancreatic cancer:~  o An alternate chemotherapeutic agent was an acceptable substitute as 1st-line therapy in the event that the subject was intolerant to or ineligible to receive gemcitabine~* ≥ 2 weeks elapsed from the completion of previous chemotherapy, and subjects must have recovered or been at new stable baseline from any related toxicities~Exclusion Criteria:~* More than 1 prior chemotherapy regimen (not including adjuvant therapy) for metastatic disease~* Evidence of central nervous system (CNS) metastases (unless stable for \> 3 months) or history of uncontrolled seizures~* Ongoing radiation therapy or prior radiation therapy administered as a second-line treatment~* Other active malignancy except basal or squamous carcinoma of the skin~* Inability to swallow food or any condition of the upper GI tract that precluded administration of oral medications~* Inadequate renal, hepatic and bone marrow function demonstrated by clinical observations and/or laboratory assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Capecitabine and ruxolitinib (Type: EXPERIMENTAL): None
- Capecitabine and placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gait Modification Treatments for Knee Pathology

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80~* Ambulatory~* Symptomatic knee pain ≥ 3/10 on most of the past 30 days~* Prior ACL injury/surgery, meniscus injury/surgery, and/or physician-diagnosed medial compartment knee osteoarthritis (KL grade 1-3)~* Agreement and ability to use provided interventions during the study period (suggested cumulative wear time during walking of 1-2 hr/day)~* Committed to not starting any new therapies for knee condition during the trial, other than rescue pain medication.~Exclusion Criteria:~* Use of walking aid (e.g. cane, crutch, walker, or wheelchair)~* BMI ≥ 35 kg/m2~* Injection in the affected knee during the previous three months~* Known neuropathy due to diabetes or other causes~* Inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Experimental Treatment A then B (Type: EXPERIMENTAL): Subjects will receive two treatments: (1) a non-invasive external Cutaneous Stimulation device placed on the leg of the subject consisting of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback (vibration) to the subject and (2) a commercially-available knee sleeve, separated by a washout period.
- Experimental Treatment B then A (Type: EXPERIMENTAL): Subjects will receive two treatments: (1) a commercially-available knee sleeve and (2) a non-invasive external Cutaneous Stimulation device placed on the leg of the subject consisting of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback (vibration) to the subject, separated by a washout period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects presenting a diagnosis of peripheral neuropathic pain, defined as pain caused by a lesion of the peripheral nervous system manifesting with sensory symptoms and signs, for at least 6 months at screening.~* At baseline, subjects must have completed at least 4 daily pain diaries and must have a mean weekly pain score equal or greater than 4.~Exclusion Criteria:~* Presence of any of the following diagnoses: Cervical or lumbo-sacral radiculopathy; Operated or non-operated chronic low back pain Carpal tunnel syndrome or any other entrapment-related neuropathic pain (defined as pain associated with focal nerve lesion produced by constriction or mechanical distortion of the nerve, within a fibrous or fibro-osseous tunnel, or by a fibrous band) ; Complex regional pain syndrome (type 1 and 2); Fibromyalgia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients with a diagnosis of Alzheimer's disease according to the National Institute of Neurological and Communicative Disorders and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria~* Having a Mini-Mental Status Examination (MMSE) score of 10 - 22 inclusive~* Having an Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog) score of at least 18~* Exhibiting an onset and progression of cognitive dysfunction during at least 6 months prior to the screening period~Exclusion Criteria:~* Patients with neurodegenerative diseases other than Alzheimer's disease, such as Lewy bodies disease, (dementia due to tiny round structures made of proteins that develop within nerve cells in the brain), Parkinsonism, etc~* Patients with cognitive dysfunction due to cerebral damage resulting from a lack of oxygen, a brain injury, etc~* Patients with multi-infarct dementia (brought on by a series of strokes) or active cerebrovascular disease~* Patients with clinically significant cardiovascular disease~* Patients currently taking drugs such as a cholinesterase inhibitors, which improve cerebral circulation/metabolism

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Galantamine 16 mg/day (Type: EXPERIMENTAL): None
- Galantamine 24 mg/day (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* polycythemia vera diagnosed according to PVSG criteria, modified by Pearson~* Previously untreated patients or patients treated by phlebotomy only or HU or pipobroman for less than 2 years~* Age 18 to 65 years~* Signed informed consent~Exclusion Criteria:~* Contra indication for interferon~* Severe renal or liver disease~* ECOG performance status \> 2~* Pregnancy~* Uncontrolled endocrine disorders except well regulated hyperthyroidism and diabetes~* Severe concomitant heart failure or psychiatric disorder~* Patients receiving an other investigational treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed or refractory Hodgkin lymphoma following failure of standard frontline chemotherapy for the treatment of classical Hodgkin lymphoma~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~Exclusion Criteria:~* Previously treated with brentuximab vedotin, immune-oncology agents, or received an allogeneic or autologous stem cell transplant~* Documented history of a cerebral vascular event~* History of another invasive malignancy that has not been in remission for at least 3 years~* History of progressive multifocal leukoencephalopathy (PML)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brentuximab Vedotin + Nivolumab (Type: EXPERIMENTAL): Brentuximab vedotin plus nivolumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Virtual Reality Pain Neuroscience Education for Middle School Students

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* willing to view VR educational session~* in grades 5, 6, 7, or 8.~Exclusion Criteria:~* has been through PNE educational program previously~* aversion to VR or problems with viewing VR in the past~* history of epilepsy or seizures~* eye surgery or injury within the last 6 months~* open sores or wounds around where VR googles are worn on face~* anyone who has had a concussion that has not been cleared for full activity or experiencing any post-concussion syndrome symptoms currently.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- VR pain education (Type: EXPERIMENTAL): Students receiving the 45 minute pain education through Virtual Reality

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female MG patients age greater than 18 and less than 65 years~* Onset of generalized MG within the last 5 years~* Positive serum anti-acetylcholine receptor binding antibodies (muscle acetylcholine receptors, AchRAb =/\> 1.00 nmol/L. AchRAb levels of 0.50-0.99 nmol/L will be acceptable if there is another confirmatory test for MG, including single-fiber electromyography (EMG), repetitive nerve stimulation, or unequivocal edrophonium testing.)~* MGFA class II-IV at entry, using the MG Foundation of America (MGFA) classification, while receiving optimal anti-cholinesterase treatment with or without oral prednisone~Exclusion Criteria:~* Ocular MG without generalized weakness (MGFA Class I) or minimal weakness that would not require the use of corticosteroids~* Myasthenic weakness requiring intubation (MGFA Class IV) in the prior month~* Immunosuppressive therapy other than corticosteroids in the preceding year~* Medically unfit for thymectomy~* Chest CT evidence of thymoma.~* Pregnancy or lactation; contraindications to the use of corticosteroids, unless postmenopausal or surgically sterile. Women considering becoming pregnant during the period of the study are to be excluded.~* A serious concurrent medical, neurological or psychiatric condition that would interfere with thymectomy or subsequent clinical assessments~* Current alternate day dose of prednisone \> than 1.5 mg/kg or 100 mg or the equivalent daily doses (\> 0.75 mg/kg or 50 mg).~* Participation in another experimental clinical trial~* History of alcohol or drug abuse within the 2 years prior to randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Thymectomy plus prednisone (Type: ACTIVE_COMPARATOR): Procedure: Extended Transsternal Thymectomy plus prednisone treatment
- Prednisone alone (Type: PLACEBO_COMPARATOR): Drug: prednisone alone protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete